Bibliography
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9
- Giacomini KM, Krauss RM, Roden DM, When good drugs go bad. Nature 2007;446:975-7
- Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83
- Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today 2009;14:343-57
- Harmark L, Van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52
- Ajayi FO, Sun H, Perry J. Adverse drug reactions: a review of relevant factors. J Clin Pharmacol 2000;40:1093-101
- Trifiro G, Pariente A, Coloma PM, Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009;18:1176-84
- Krejsa CM, Horvath D, Rogalski SL, Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Devel 2003;6:470-80
- Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
- Whitebread S, Hamon J, Bojanic D, In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-33
- Sanguinetti MC, Tristani-Firouzi M. hERG potassium channel and cardiac arrhythmia. Nature 2006;440:463-9
- Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9
- Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today 2009;14:479-85
- Mestres J, Gregori-Puigjane E, Valverde S, Data completeness: the Achilles heel of drug-target networks. Nat Biotechnol 2008;26:983-4
- Mestres J, Gregori-Puigjane E, Valverde S, The topology of drug-target interactions: implicit dependence on drug properties and target families. Mol BioSyst 2009;5:1051-7
- Vogt I, Mestres J. Drug-target networks. Mol Inf 2010;29:10-14
- Keiser MJ, Roth BL, Armbruster BN, Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197-206
- Gregori-Puigjane E, Mestres J. Ligand-based approach to mining the chemogenomic space of drugs. Comb Chem High Throughput Screen 2008;11:669-76
- Campillos M, Kuhn M, Gavin A-C, Drug target identification using side-effect similarity. Science 2008;321:263-6
- Keiser MJ, Setola V, Irwin JJ, Predicting new molecular targets for known drugs. Nature 2009;462:175-82
- Campillos M, Kuhn M, Gavin A-C, Drug target identification using side-effect similarity. Science 2008;321:263-6
- Fliri AF, Loging WT, Thadeio PF, Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 2005;1:389-97
- Bender A, Scheiber J, Glick M, Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2:861-73
- Vidal D, Mestres J. In silico receptorome screening of antipsychotic drugs. Mol Inf 2010;29:543-51
- Henegar C, Bousquet C, Lillo-Le Louet A, Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance. Comput Biol Med 2006;36:748-67
- World Drug Index. Available from: http://thomsonreuters.com/products_ services/science/science_products/a-z/world_drug_index
- Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004;32:D267-70, Available from: http://www.nlm.nih.gov/research/umls/
- MeSH. Available from: http://www.ncbi.nlm.nih.gov/mesh
- Dailymed. Available from: http://dailymed.nlm.nih.gov
- Drug Information Online. Available from: http://www.drugs.com
- MedlinePlus. Available from: http://medlineplus.gov
- Medscape. Available from: http://www.medscape.com
- ToxNet. Available from: http://toxnet.nlm.nih.gov
- WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2010. Oslo, 2009. Available from: http://www.whocc.no
- ChEMBL database. Available from: (http://www.ebi.ac.uk/chembldb)
- Psychoactive Drug Screening Program. Available from: http://pdsp.med.unc.edu
- Liu T, Lin Y, Wen X, BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198-201
- Harmar AJ, Hills RA, Rosser EM, IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res 2009;37:D680-5
- Garcia-Serna R, Ursu O, Oprea TI, iPHACE: integrative navigation in pharmacological space. Bioinformatics 2010;26:985-6
- Scheiber J, Jenkins JL, Sukuru SCK, Mapping adverse drug reactions in chemical space. J Med Chem 2009;52:3103-7
- Fliri AF, Loging WT, Volkmann RA. Drug effects viewed from a signal transduction network perspective. J Med Chem 2009;52:8038-46
- Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007;152:9-20
- Rognan D. Structure-based approaches to target fishing and ligand profiling. Mol Inf 2010;29:176-87
- Ratner Y, Gibel A, Yorkov B, Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1401-9
- Kuhn M, Campillos M, Letunic I, A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343
- Yang L, Luo H, Chen J, SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucl Acids Res 2009;37:W406-12
- Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen-phen’. Expert Opin Drug Metab Toxicol 2005;1:377-87
- Anari MR, Baillie TA. Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discov Today 2005;10:711-17
- Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192:23-32
- Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007;6:202-10
- Scheiber J, Chen B, Milik M, Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 2009;49:308-17
- Tatonetti NP, Liu T, Altman RB. Predicting drug side-effects by chemical systems biology. Genome Biol 2009;10:238
- Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009;154:277-87